# CME Group Inc.: overview

CME · Nasdaq · CIK 1156375 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cme.md) · [Financials](/companies/cme/financials.md) · [Filings](/companies/cme/filings.md) · [Insiders](/companies/cme/insiders.md)

Latest reported revenue: [$1.74bn](/filings/0001156375-26-000068.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 23, 2026 (XBRL us-gaap:Revenues, accession 0001156375-26-000068).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,525 d](/filings/0001156375-26-000009.md) | [1,642](/filings/0001156375-26-000020.md) | [1,692](/filings/0001156375-26-000047.md) | [1,538](/filings/0001156375-26-000068.md) | [1,649 d](/filings/0001156375-26-000009.md) | [1,880](/filings/0001156375-26-000020.md) | [1,706](/filings/0001156375-26-000047.md) | [1,737](/filings/0001156375-26-000068.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [62.1% d](/filings/0001156375-26-000009.md) | [67.5%](/filings/0001156375-26-000020.md) | [66.7%](/filings/0001156375-26-000047.md) | [63.3%](/filings/0001156375-26-000068.md) | [61.8% d](/filings/0001156375-26-000009.md) | [69.7%](/filings/0001156375-26-000020.md) | [64.9%](/filings/0001156375-26-000047.md) | [65.7%](/filings/0001156375-26-000068.md) |
| Net margin | % | [57.3% d](/filings/0001156375-26-000009.md) | [58.2%](/filings/0001156375-26-000020.md) | [60.6%](/filings/0001156375-26-000047.md) | [59.1%](/filings/0001156375-26-000068.md) | [71.7% d](/filings/0001156375-26-000009.md) | [61.4%](/filings/0001156375-26-000020.md) | [61.1%](/filings/0001156375-26-000047.md) | [59.7%](/filings/0001156375-26-000068.md) |
| Diluted EPS | $ per share | not reported | [2.62](/filings/0001156375-26-000020.md) | [2.81](/filings/0001156375-26-000047.md) | [2.49](/filings/0001156375-26-000068.md) | not reported | [3.18](/filings/0001156375-26-000020.md) | [2.88](/filings/0001156375-26-000047.md) | [2.89](/filings/0001156375-26-000068.md) |
| Free cash flow | $m | [992 d](/filings/0001156375-26-000009.md) | [1,102](/filings/0001156375-26-000020.md) | [1,040 d](/filings/0001156375-26-000047.md) | [950 d](/filings/0001156375-26-000068.md) | [1,101 d](/filings/0001156375-26-000009.md) | [1,238](/filings/0001156375-26-000020.md) | [924 d](/filings/0001156375-26-000047.md) | [1,070 d](/filings/0001156375-26-000068.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,690](/filings/0001156375-24-000010.md) | [5,019](/filings/0001156375-25-000021.md) | [5,579](/filings/0001156375-26-000009.md) | [6,130](/filings/0001156375-26-000009.md) | [6,521](/filings/0001156375-26-000009.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [56.4%](/filings/0001156375-24-000010.md) | [60.1%](/filings/0001156375-25-000021.md) | [61.6%](/filings/0001156375-26-000009.md) | [64.1%](/filings/0001156375-26-000009.md) | [64.9%](/filings/0001156375-26-000009.md) |
| Net margin | % | [56.2%](/filings/0001156375-26-000009.md) | [53.6%](/filings/0001156375-26-000009.md) | [57.8%](/filings/0001156375-26-000009.md) | [57.5%](/filings/0001156375-26-000009.md) | [62.5%](/filings/0001156375-26-000009.md) |
| Diluted EPS | $ per share | [7.29](/filings/0001156375-24-000010.md) | [7.40](/filings/0001156375-25-000021.md) | [8.86](/filings/0001156375-26-000009.md) | [9.67](/filings/0001156375-26-000009.md) | [11.16](/filings/0001156375-26-000009.md) |
| Free cash flow | $m | [2,275](/filings/0001156375-24-000010.md) | [2,966](/filings/0001156375-25-000021.md) | [3,377](/filings/0001156375-26-000009.md) | [3,597](/filings/0001156375-26-000009.md) | [4,194](/filings/0001156375-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cme/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Cutinho Sunil](/insiders/1619400.md) | Chief Information Officer, Officer | Sale (S) | 5,000 | $298.70 | $1.5m | [Form 4](/filings/0001619400-26-000005.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.75bn | 30,566,342 |  | Reduced −881,915 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.23bn | 23,661,856 |  | Added +294,574 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.61bn | 16,346,170 |  | Added +290,883 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $2.15bn | 9,728,195 |  | Added +321,352 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.05bn | 9,271,309 |  | Added +124,421 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.02bn | 9,167,524 |  | Added +138,235 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $1.51bn | 6,822,315 |  | Reduced −114,173 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.26bn | 5,767,731 |  | Reduced −6,442,030 |
| [Sanders Capital, LLC](/funds/1508097.md) | 2026-06-30 | $1.12bn | 5,067,740 |  | Added +906,550 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $1.06bn | 4,820,646 |  | New +4,820,646 |

## Recent filings

[All 2,325 filings](/companies/cme/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 14:22 ET | [10-Q](/filings/0001156375-26-000068.md) | Quarterly report, period 2026-09-30 | 0001156375-26-000068 |
| 2026-10-21 | 07:13 ET | [8-K](/filings/0001156375-26-000065.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001156375-26-000065 |
| 2026-09-25 | 16:08 ET | [8-K](/filings/0001156375-26-000060.md) | 5.03 Amendment to articles or bylaws | 0001156375-26-000060 |
| 2026-09-09 | 11:15 ET | [8-K](/filings/0001193125-26-386091.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-386091 |
| 2026-08-11 | 16:44 ET | [8-K](/filings/0001156375-26-000051.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001156375-26-000051 |
| 2026-07-24 | 14:43 ET | [10-Q](/filings/0001156375-26-000047.md) | Quarterly report, period 2026-06-30 | 0001156375-26-000047 |
| 2026-07-22 | 07:15 ET | [8-K](/filings/0001156375-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001156375-26-000042 |
| 2026-06-17 | 08:35 ET | [8-K](/filings/0001193125-26-273442.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-273442 |
| 2026-06-10 | 16:50 ET | [8-K](/filings/0001156375-26-000035.md) | 5.07 Shareholder vote results | 0001156375-26-000035 |
| 2026-05-19 | 16:21 ET | [8-K](/filings/0001156375-26-000028.md) | 5.07 Shareholder vote results | 0001156375-26-000028 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001156375-26-000009.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1156375
- Tickers: CME
- Exchange: Nasdaq
- SIC code: 6200 Security & Commodity Brokers, Dealers, Exchanges & Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:17 ET. No prices; not investment advice.